SHIfT was an international, multicenter, randomized, double-blind, placebo-controlled, parallel-group, event-driven study conducted in 677 centers in 37 countries and randomized 6505 heart failure patients for a median duration of 22.9 months and up to 41.7 months.1

SHIFT_02

Ivabradine or placebo on top of guideline-recommended therapy including ACE inhibitor,
β-blocker, mineralocorticoid receptor antagonist.

1. Swedberg K, et al. Eur J Heart Fail. 2010;12(1):75-81.
  • stable symptomatic chronic heart failure (NYHA class II to IV)
  • prior hospitalization for worsening heart failure within the previous 12 months
  • left ventricular systolic dysfunction defined by an ejection fraction ≤35%
  • sinus rhythm with heart rate ≥70 bpm1

    • 1. Swedberg K, et al. Eur J Heart Fail. 2010;12(1):75-81.
Ivabradine or placebo were given on top of optimal guidelines-based treatment.

The ivabradine dose could be adjusted at each follow-up visit according to heart rate and tolerability.1


1. Swedberg K, et al. Lancet. 2010;376(9744):875-885.